Compare ORGN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORGN | GLSI |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.4M | 123.9M |
| IPO Year | N/A | 2020 |
| Metric | ORGN | GLSI |
|---|---|---|
| Price | $0.25 | $13.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $39.00 |
| AVG Volume (30 Days) | ★ 1.6M | 334.1K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,122,000.00 | N/A |
| Revenue This Year | $49.18 | N/A |
| Revenue Next Year | $144.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $7.78 |
| 52 Week High | $1.36 | $14.47 |
| Indicator | ORGN | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 18.76 | 78.39 |
| Support Level | $0.43 | $10.00 |
| Resistance Level | $0.46 | $13.76 |
| Average True Range (ATR) | 0.04 | 1.17 |
| MACD | -0.02 | 0.43 |
| Stochastic Oscillator | 0.00 | 86.56 |
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.